2011 ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): Highlights for the clinician

Clinical Cardiology

Volumn 35, Issue 1, 2012, Pages 3-8

  Wenger, Nanette K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DABIGATRAN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; OMEPRAZOLE; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIAC PATIENT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; INVASIVE PROCEDURE; LOW DRUG DOSE; MEDICAL SOCIETY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; REVIEW; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

AMERICAN HEART ASSOCIATION; ANGINA, UNSTABLE; ANGIOPLASTY, BALLOON, CORONARY; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84855655812     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20964     Document Type: Review

References (38)

1. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST- Segment Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011; 57: 1920-1959.
2. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003; 290: 1593-1599. (Pubitemid 37441261)
3. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009; 360: 2165-2175.
4. Montalescot G, Cayla G, Collet JP, et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA. 2009; 302: 947-954.
5. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015. (Pubitemid 350106708)
6. Mehta SR, Tanquay JF, Elkelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010; 376: 1233-1243.
7. Mehta SR, Bassand JP, Chrolavicius S, et al. for the CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010; 363: 930-942.
8. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057.
9. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, American Heart Association, Society of Cardiovascular Angiography and Interventions, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. J Am Coll Cardiol. 2010; 56: 321-341.
10. Mega KL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009; 119: 2553-2560.
11. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009; 30: 1744-1752.
12. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010; 363: 1909-1917.
13. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2010; 56: 2051-2066.
14. Giugliano RP, White JA, Bode C, et al. Early versus delayed provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009; 360: 2176-2190.
15. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007; 297: 591-602.
16. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009; 32: 1119-1131.
17. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009; 54: 2205-2241.
18. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360: 1283-1297.
19. Kosiborod M, Inzucchi SE, Goyal A, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA. 2009; 301: 1556-1564.
20. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999; 99: 2626-2632. (Pubitemid 29237448)
21. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006; 354: 449-461. (Pubitemid 43200296)
22. Januzzi JL, Cannon CP, DiBattiste PM, et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndrome (the TACTICS-TIMI 18 Trial). Am J Cardiol. 2002; 90: 1246-1249. (Pubitemid 35350859)
23. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002; 137: 563-570.
24. Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009; 4: 1032-1043.
25. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010; 121: 357-365.
26. Erley CM., Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant. 1999; 14: 1064-1066. (Pubitemid 29209281)
27. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994; 331: 1416-1420. (Pubitemid 24348355)
28. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002; 90: 1068-1073. (Pubitemid 35335595)
29. Laskey WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007; 50: 584-590. (Pubitemid 47199002)
30. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009; 120: 851-858.
31. Krumholtz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation. 2008; 118: 2596-2648.
32. American Heart Association. Get With the Guidelines. Accessed June 10, 2009.
33. National Cardiovascular Data Registry. Action RegistryGWTG. Accessed June 10, 2009.
34. QualityNet.com. Measure Comparison (Inpatient Hospital Quality Measures). Accessed June 10, 2009.
35. The Joint Commission. Acute Myocardial Infarction Core Measure Set. Accessed June 10, 2009.
36. The FUTURA/OASIS-8 Randomized Trial. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux. JAMA. 2010; 304: 1339-1349.
37. Brilinta (ticagrelor) [package insert]. Wilmington, DE: AstraZeneca.
38. Connolly SJ, Esekowitz MD, Yusuf S, et al. for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.